Schizophrenia Research
Volume 84, Issue 2 , Pages 204-213, June 2006

Protein expression profiling of postmortem brain in schizophrenia

  • Jianfeng Mei

      Affiliations

    • Ciphergen Biosystems, Inc., 6611 Dumbarton Circle, Fremont, CA 94555, United States
    • Present Address: Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, P.O. 208066, New Haven, CT 06520-8066, United States.
  • ,
  • Daniel Kolbin

      Affiliations

    • Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States
  • ,
  • Hung-Teh Kao

      Affiliations

    • Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States
    • Present Address: B. Porton and H.-T. Kao contributed equally to this work.
  • ,
  • Barbara Porton

      Affiliations

    • Nathan Kline Institute for Psychiatric Research and Department of Psychiatry, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States
    • Present Address: B. Porton and H.-T. Kao contributed equally to this work.
    • Corresponding Author InformationCorresponding author. Tel.: +1 845 398 2070; fax: +1 845 398 5422.

Received 7 December 2005; received in revised form 15 February 2006; accepted 17 February 2006.

Abstract 

Surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) enables the sensitive, high-throughput protein profiling of complex biological mixtures. In combination with bioinformatics, this technology has the potential to identify combinations of spectral peaks that can differentiate individuals with a particular disease from normal controls. SELDI-TOF-MS was used to screen postmortem tissue derived from the dorsolateral prefrontal cortex of individuals with schizophrenia (n=34) and matched controls (n=35), obtained from the Stanley Foundation Neuropathology Consortium. Tissue samples were homogenized in urea buffer, applied to four different chip arrays which possess different chromatographic surfaces, and analyzed using the Ciphergen ProteinChip® Biomarkers System (Model PBS II). Protein expression profiles of the schizophrenia and control groups were compared and analyzed using the Ciphergen Express (CE) and Biomarker Patterns Software (BPS) package. We detected several protein peaks whose intensities differed between the schizophrenia and control groups to a highly significant degree. A combination of these peaks was capable of distinguishing between schizophrenia and controls with a sensitivity and specificity of about 70%. The classification model that distinguished schizophrenia from controls was complex, suggesting that the biochemical abnormalities underlying schizophrenia are heterogeneous. Our results suggest that SELDI-TOF-MS has the potential for distinguishing individuals with schizophrenia from normal controls and may eventually lead to a better understanding of the classification, diagnosis and pathogenesis of this disorder.

Keywords: Protein chip, Proteomics, Biomarker, Model

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-9964(06)00084-3

doi:10.1016/j.schres.2006.02.016

Schizophrenia Research
Volume 84, Issue 2 , Pages 204-213, June 2006